Florida seeks to recover Medicaid-related Vioxx expenses
This article was originally published in Scrip
Florida's state government has filed suit against Merck & Cofor allegedly misrepresenting the cardiovascular risks of the withdrawn painkiller Vioxx (rofecoxib), joining over a half dozen US states and New York City who have sued for Medicaid-related expenses since the drug was withdrawn four years ago. They all seek to recover money spent in state healthcare programmes on the product, claiming that Merck's actions caused the states to pay for drugs prescribed under false pretences – and all of the suits are pending in the federal multi-district proceedings in New Orleans, except for a Texas proceeding which is pending in state court.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.